The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter clinical randomized phase II study of investigating duration of adjuvant chemotherapy with S-1 (six versus 12 months) for patients with resected pancreatic cancer: PACS-1 study.
 
Yo-ichi Yamashita
No Relationships to Disclose
 
Shinji Itoh
No Relationships to Disclose
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Hiroshi Takamori
No Relationships to Disclose
 
Kengo Fukuzawa
No Relationships to Disclose
 
Mizuki Ninomiya
No Relationships to Disclose
 
Kenichiro Araki
No Relationships to Disclose
 
Kiyoshi Kajiyama
No Relationships to Disclose
 
Keishi Sugimachi
No Relationships to Disclose
 
Hideaki Uchiyama
No Relationships to Disclose
 
Yuji Morine
No Relationships to Disclose
 
Tohru Utsunomiya
No Relationships to Disclose
 
Tadashi Uwagawa
No Relationships to Disclose
 
Takashi Maeda
No Relationships to Disclose
 
Eisuke Adachi
No Relationships to Disclose
 
Yasuharu Ikeda
No Relationships to Disclose
 
Tomoharu Yoshizumi
No Relationships to Disclose
 
Hideo Baba
Honoraria - Lilly; Lilly; Lilly; Lilly
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); MSD K.K (Inst); MSD K.K (Inst); MSD K.K (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Shin Nippon Biomedical (Inst); Shin Nippon Biomedical (Inst); Shin Nippon Biomedical (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Masaki Mori
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)